MENU
TMDX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

TMDX stock forecast, quote, news & analysis

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states... Show more

TMDX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for TMDX with price predictions
Jul 31, 2026

TMDX in upward trend: price rose above 50-day moving average on July 13, 2026

TMDX moved above its 50-day moving average on July 13, 2026 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on TMDX as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TMDX just turned positive on July 07, 2026. Looking at past instances where TMDX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for TMDX crossed bullishly above the 50-day moving average on July 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

TMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 270 cases where TMDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.353) is normal, around the industry mean (10.948). P/E Ratio (17.508) is within average values for comparable stocks, (63.950). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.043). TMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (4.766) is also within normal values, averaging (35.779).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.74B. The market cap for tickers in the group ranges from 1.86K to 182.9B. ABT holds the highest valuation in this group at 182.9B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 3%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -18%. GCTK experienced the highest price growth at 64%, while CODX experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 16%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 75
Price Growth Rating: 62
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
TMDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of a proprietary system for preserving human organs for transplant

Industry MedicalNursingServices

Profile
Details
Industry
Medical Specialties
Address
200 Minuteman Road
Phone
+1 978 552-0900
Employees
584
Web
https://www.transmedics.com
TMDX in upward trend: price rose above 50-day moving average on July 13, 2026